Replies to post #22374 on Biotech Values

[drbio45]

dor is undervalued

the overhang has been the amex listing which still isn't resolved. The six million isn't in the bank.

They need to get money in the bank

[io_io]

DOR:

Dor has jumped, and this news from last week (and I don't think anyone posted it here) puts a floor in it. It seems a little jaded, but the fact is that a ton of cash exists for the purpose of anti-terror vaccines, and ricin was one of the targetted threats for this purpose.

Still only $25m-$30m market cap. I have a ton, but may buy more in the morning.

editted for brevity:


DOR BioPharma Announces Positive Phase I Results of RiVax(TM), Its Vaccine Against Ricin Toxin
Tuesday January 31, 9:13 am ET


Vaccine Is Immunogenic and Well Tolerated


MIAMI, FL--(MARKET WIRE)--Jan 31, 2006 -- DOR BioPharma, Inc. (AMEX:DOR - News) ("DOR," or the "Company") today announced results of a Phase I clinical trial of RiVax(TM), a recombinant vaccine against ricin toxin, that has been completed by investigators at the University of Texas Southwestern Medical Center (UT Southwestern) led by Dr. Ellen Vitetta, director of the Cancer Immunobiology Center at UT Southwestern. The results of the Phase I safety and immunogenicity dose-escalation study indicate that the vaccine is well tolerated and induces antibodies in humans that neutralize ricin toxin. The outcome of the study will be published this week in the online edition of the Proceedings of the National Academy of Sciences.

The pilot Phase I dose escalation clinical trial of RiVax(TM) marks the first time a ricin toxin vaccine has ever been clinically tested in humans. The trial enrolled 15 volunteers in groups of 5 who were vaccinated with three successive monthly injections of the same dose level of RiVax(TM). Three dose levels of RiVax(TM) were evaluated. The vaccine was prepared without an adjuvant to determine whether the subunit itself was immunogenic and safe. Even without an adjuvant, RiVax(TM) induced antibodies in all five of the individuals who received the highest dose, four out of five who received the intermediate dose, and one out of five who received the lowest dose levels. The vaccine was well tolerated in all individuals with only mild side effects that are typical of reactions to vaccines injected intramuscularly. These side effects included mild transient headaches and sore arms.

Despite the absence of an adjuvant, antibodies were present in the blood of several volunteers for as long as 127 days after their last vaccination. The functional activity of the antibodies was confirmed by transferring serum globulins from the vaccinated individuals along with active ricin toxin to sensitive mice, which then survived the treatment.

During the past decade, the Department of Defense (DOD) has identified the development of a safe and effective ricin vaccine as one of its eight top development priorities and is currently exploring the feasibility of available technologies to address that need. Under the BioShield I Act, the government can authorize, purchase, and use these vaccines as early as Phase I clinical testing, before a vaccine is fully licensed by the Food and Drug Administration (FDA). The next steps for the development of RiVax(TM) will include extensive evaluation to correlate protection against ricin exposure in animals to immune responses in vaccinated humans.